tiprankstipranks
Trending News
More News >

iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision

As previously reported, Wedbush analyst David Nierengarten downgraded iTeos Therapeutics (ITOS) to Neutral from Outperform with a price target of $12, up from $10, after the company announced plans to wind down operations and explore asset sales from its pipeline. The company maintained a cash position of $624M as of March 31, notes the firm, which anticipates cash of $530M, or $12 per share, in one year based on severance and wind-down costs of over $57M.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue